# FDA 483 - Alexion Pharma International Operations Unlimited Co. - January 24, 2023

Source: https://www.globalkeysolutions.net/records/483/alexion-pharma-international-operations-unlimited-co/1b0fed1f-247d-4950-a27f-5b9cd18b800d

> FDA 483 for Alexion Pharma International Operations Unlimited Co. on January 24, 2023. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Alexion Pharma International Operations Unlimited Co.
- Inspection Date: 2023-01-24
- Product Type: drugs
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)

## Related Documents

- [483 - 2023-01-24](https://www.globalkeysolutions.net/records/483/alexion-pharma-international-operations-unlimited-co/fb906614-0a13-4257-9c40-3fedaf01b807)
- [483 - Unknown Date](https://www.globalkeysolutions.net/records/483/alexion-pharma-international-operations-unlimited-co/eff26028-b16c-4615-8be9-b264face555f)
- [483 - 2023-01-24](https://www.globalkeysolutions.net/records/483/alexion-pharma-international-operations-unlimited-co/30dec694-8728-4299-8e51-733a5c0398aa)
- [483 - 2023-01-24](https://www.globalkeysolutions.net/records/483/alexion-pharma-international-operations-unlimited-co/85947c96-ecac-4135-9fd5-b53c5cf1e0eb)

## Related Officers

- [Mamta Kapoor-Bhushan, Pharmaceutical Scientist](https://www.globalkeysolutions.net/people/mamta-kapoor-bhushan-pharmaceutical-scientist/5a3b63c1-5098-4faf-bc13-55970643951e)
- [Jacek Cieslak, Ph.D., Lead Interdisciplinary](https://www.globalkeysolutions.net/people/jacek-cieslak-phd-lead-interdisciplinary/62581a76-407d-4666-8949-961d319345c2)
- [Zhong Li, Ph.D., Sr. Pharmaceutical Quality Assessor](https://www.globalkeysolutions.net/people/zhong-li-phd-sr-pharmaceutical-quality-assessor/cdc177bb-92f6-4d53-ba84-6e878c68917a)

Company: https://www.globalkeysolutions.net/companies/alexion-pharma-international-operations-unlimited-co/8da873c2-2cc1-4ece-9643-0f90227f6f9f

Office: https://www.globalkeysolutions.net/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd